PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News : Onxeo SA (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, Nasdaq OMX Copenhagen - ONXEO), an innovative company specialised in orphan oncology treatments, has strengthened its management team with three new senior appointments. •Elisabeth Carstensen appointed Director of Alliance Management •Graham Dixon appointed CSO/Head of R&D •Audrey Legentil-Duméry appointed Director of Human Resources Judith Greciet, CEO of Onxeo, declared: “Significantly strengthening our executive management team goes hand in hand with the implementation of our strategic growth plan. Partnerships, R&D and HR are all crucial to accelerating our development and succeeding in our ambition to become a global leader in orphan oncology. Stemming from varied cultural backgrounds and perfectly accustomed to operating in the biotech universe, I am convinced that Elisabeth, Graham and Audrey will greatly contribute to Onxeo’s future development.” Elisabeth Carstensen, Director of Alliance Management Elisabeth will head a newly created department responsible for coordinating and optimising Onxeo’s relationships with commercial as well as international development partners, significant sources of revenues for the company. Elisabeth Carstensen holds a PhD in organic chemistry and a Master’s degree in chemical engineering from the Technical University of Denmark. Initially responsible for the pharmaceutical development of Belinostat, Elisabeth was lately Director of Business Development and Partnership Management with Topotarget. Elisabeth has also been appointed Director of Onxeo’s Danish operation, ensuring the link between the group’s two entities. Graham Dixon, CSO/ Head R&D Heading the R&D department, Graham Dixon, will be responsible with his teams for leading project development up through commercialisation, strengthening portfolio projects and fostering collaboration with academic experts on promising programmes. Graham Dixon has a twenty year track record in research and development in pharmaceutical industry, particularly oncology, having held senior management positions within big pharma and biotech. For nearly ten years, Graham worked as Director of R&D with the European biotech Galapagos, accompanying its growth and international development. Graham Dixon holds a PhD in Biochemistry from the University of Swansea, Wales and an honors degree in Biology from the Universtiy of Bradford. He has numerous patents and scientific publications. Audrey Legentil-Duméry, Director of Human Resources A human resources department, headed by Audrey Legentil-Duméry, has been created to support Onxeo’s rapid growth and will support international development and talent management, notably in the integration of the French and Danish teams. Previously, Audrey Legentil-Duméry worked as a Senior HR consultant with a Paris -based agency, managing HR on behalf of diverse companies, notably accompanying SME’s through periods of growth and transition. Audrey successfully conducted several missions in the pharma and biotech sectors. Audrey holds a Master in Management and Intercultural Communication from CELSA (Sorbonne, Paris). Pierre Attali, MD, MSc, General Deputy Manager in charge of Strategy and Medical Affairs, is leaving the company to focus on other projects and may continue to collaborate with Onxeo as an advisor. About Onxeo Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives. Key products at advanced development stage are: Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma For more information, visit the website www.onxeo.com Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward -looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf-france.org) or on the company’s website (www.onxeo.com) Contacts Onxeo Judith Greciet, CEO j.greciet@onxeo.com or Nicolas Fellmann, CFO n.fellmann@onxeo.com +33 1 45 58 76 00 or Alize RP Caroline Carmagnol / Sophie Colin, +33 6 64 18 99 59 / +33 1 44 54 36 62 onxeo@alizerp.com
Onxeo Strengthens Its Executive Management Team PARIS
Top 10 Most Recent News Articles
AI-Driven Software Growth Faces Profitability Hurdles
AI and Growth: A Tale of Two Strategies Is AI the superhero we’ve been waiting for, or just another fad? The KeyBanc Capital Markets' 2026 AI x Software Benchmark throws more questions into the ring than it answers. This benchmark isn't just numbers on a page; it's a pulse check on how AI is reshaping the software landscape. Seeing AI-native firms grow at a dizzying 34%...
Continue Reading
WeFetch AI: A New Era in Barcode Precision
WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...
Continue Reading
Dana Concludes Tender Offers for Senior Notes
An Investor's Glance at Dana's Strategic Moves Dana Incorporated (NYSE: DAN) just pulled a bold move with their tender offers, snapping up a hefty $357,873,000 in outstanding principal on their senior notes. This isn’t just pocket change; folks holding out for securities can feel the tension of watching big numbers get shuffled around. You gotta wonder, what's the play...
Continue Reading
Noël Jolié's Cream Earns Spot on Oprah's List
The Powerhouse of Oprah's Seal of Approval Ever notice what happens when Oprah drops a nod towards any brand? It's like Midas touching everything gold. That's exactly the scenario with Noël Jolié, a Chicago-based luxury body care operation, hitting the jackpot by landing its Velours Silken Body Cream on Oprah's Favorite Things 2026. You can't buy this kind of press,...
Continue Reading
Euroandinos Paita Closes Consent for 2037 Notes
Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...
Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact
A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...
Continue Reading
PangeAI and Sky Blue Transform Data Center Decisions
Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...
Continue Reading
Will Hair Loss Drugs Challenge Transplant Clinics?
Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...
Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early
Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...
Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm
KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...
Continue ReadingTop 5 Most Recently Viewed Articles
Transforming a Small Investment in Royal Caribbean Into Wealth
The Power of Long-Term Investing in Royal Caribbean Investing in the stock market can often seem intimidating, especially for newcomers. However, a closer look at companies like Royal Caribbean Gr (NASDAQ: RCL) demonstrates the potential rewards of disciplined investing over time. Having shown remarkable performance, Royal Caribbean has an annualized return that exceeds...
Continue Reading
Immuron's Financial Growth and Clinical Progress Update
Immuron's Consistent Growth and Exciting Projects Update Immuron Limited, a biopharmaceutical company based in Australia and publicly traded on the NASDAQ under the ticker IMRN and ASX ticker IMC.AX, is announcing some significant updates that reflect its ongoing commitment to healthcare innovation. The company's recent sales figures and progress in clinical trials...
Continue Reading
General Motors Growth Potential: Insights from Analysts
General Motors Gets a Boost from Analysts In recent developments, General Motors Company (NYSE: GM) has garnered notable attention from financial analysts, particularly following Barclays' upgrade of the stock. The analysts play a vital role in assessing the market potential for stocks, and their insights can greatly influence investor confidence. Analyst Upgrades Impact...
Continue Reading
BioAge Labs Faces Class Action Lawsuit: Deadline Approaches Soon
BioAge Labs Faces Class Action Lawsuit Investors of BioAge Labs, Inc. (NASDAQ: BIOA) are currently navigating a challenging landscape as a class action lawsuit is underway against the biopharmaceutical company. This underscores the importance for shareholders to stay informed about the developments following the company's recent stock performance and ensuing legal...
Continue Reading
Audit BEE Celebrates Dual Honors at Global Brand Awards
Audit BEE Wins Prestigious Global Brand Awards Audit BEE has achieved remarkable recognition for its Excellence in Compliance and Advisory Leadership, recently celebrated at the prestigious Global Brand Awards. These awards, organized by Global Brands Magazine, acknowledge outstanding contributions from brands worldwide, showing the importance of excellence across various...
Continue Reading